Moving Toward the Next Paradigm for Cardiovascular Prevention

Circulation

Volumn 133, Issue 16, 2016, Pages 1533-1536

  Robinson, Jennifer G ^a   Ray, Kausik ^b  

^a UNIVERSITY OF IOWA   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Editorials; guideline; prevention and control; statin therapy

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANKLE BRACHIAL INDEX; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; DECISION MAKING; HUMAN; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; BLOOD; CARDIOVASCULAR DISEASES; NUTRITION; STANDARDS; TRENDS; UNITED STATES;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NUTRITION SURVEYS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84964474527     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.022134     Document Type: Review

References (18)

1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-S45.
2. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
3. Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. Eur Heart J. 2015;36:2975-2983. doi: 10.1093/eurheartj/ehv340.
4. Robinson JG. Starting primary prevention earlier with statins. Am J Cardiol. 2014;114:1437-1442. doi: 10.1016/j.amjcard.2014.07.076.
5. Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590.
6. Thanassoulis G, Williams K, Altobelli KK, Pencina MJ, Cannon CP, Sniderman A. Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease. Circulation. 2016;133:1574-1581. doi: 10.1161/CIRCULATIONAHA.115.018383.
7. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49-S73.
8. Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406-1415. doi: 10.1001/jama.2014.2630.
9. Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. BMJ. 2000;320:1446-1447.
10. Grundy SM. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7:561-565.
11. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. Primary prevention with statins: ACC/AHA risk-based approach versus trial-based approaches to guide statin therapy. J Am Coll Cardiol. 2015;66:2699-2709. doi: 10.1016/j.jacc.2015.09.089.
12. Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314:142-150. doi: 10.1001/jama.2015.6822.
13. Robinson JG. Statins and diabetes risk: how real is it and what are the mechanisms? Curr Opin Lipidol. 2015;26:228-235. doi: 10.1097/MOL.0000000000000172.
14. Brooks JM, Cook E, Chapman CG, Schroeder MC, A Chrischilles E, Schneider KM, Kulchaitanaroaj P, Robinson J. Statin use after acute myocardial infarction by patient complexity: are the rates right? Med Care. 2015;53:324-331. doi: 10.1097/MLR.0000000000000322.
15. Yeboah J, Polonsky TS, Young R, McClelland RL, Delaney JC, Dawood F, Blaha MJ, Miedema MD, Sibley CT, Carr JJ, Burke GL, Goff DC, Psaty BM, Greenland P, Herrington DM. Utility of nontraditional risk markers in individuals ineligible for statin therapy according to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. Circulation. 2015;132:916-922. doi: 10.1161/CIRCULATIONAHA.115.016846. Epub 2015 Jul 29.
16. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, Nordio F, Hyde CL, Cannon CP, Sacks FM, Poulter NR, Sever PS, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385:2264-2271. doi: 10.1016/S0140-6736(14)61730-X.
17. Robinson JG, Stone NJ. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J. 2015;36:2110-2118. doi: 10.1093/eurheartj/ehv182.
18. Miedema MD, Lopez FL, Blaha MJ, Virani SS, Coresh J, Ballantyne CM, Folsom AR. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015;175:138-140. doi: 10.1001/jamainternmed.2014.6288.